Denosumab Improves OS in Patients with Metastatic Lung Cancer

Share this content:
(ChemotherapyAdvisor) – Patients with metastatic lung cancer and bone metastases had improved overall survival (OS) when treated with denosumab compared with zoledronic acid, results of an exploratory analysis reported in the December 2012 issue of the Journal of Thoracic Oncology.

The study reviewed survival data for a subset of patients with non-small cell lung cancer (NSCLC) and SCLC enrolled in a phase 3 trial of denosumab vs zoledronic acid for the treatment of bone metastases from solid tumors or multiple myeloma, reported Giorgio Scagliotti, MD, of the University of Torino, Torino, Italy. Those with breast or prostate cancer were excluded from the study.

Patients randomly received subcutaneous denosumab 120mg or intravenous zoledronic acid 4mg monthly.

In the 811 patients with any lung cancer, median OS with denosumab (n=411) was 8.9 months vs 7.7 months for zoledronic acid (n=400)(HR 0.80; P=0.01) and, in the 702 patients with NSCLC, 9.5 months vs 8.0 months, respectively (HR 0.78; P=0.01).

When patients with NSCLC were examined by histological type, median OS with denosumab was 8.6 months vs 6.4 months for zoledronic acid in those with squamous cell carcinoma (HR 0.68; P=0.035).

Adverse events (AEs) were balanced between treatment groups; serious AEs occurred in 66.0% of patients in the denosumab arm and 72.9% in the zoledronic acid arm. Cumulative incidence of osteonecrosis of the jaw was 0.7% and 8%, respectively, and rate of hypocalcemia was 8.6% and 3.8%.


Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs